By Helena Smolak
Sanofi backed its full-year guidance after higher first-quarter sales and profit that beat analysts' expectations.
The French pharmaceutical company said Thursday that business operating profit--one of its preferred metrics, which strips out exceptional items--rose 20% to 2.90 billion euros, equivalent to $3.28 billion, driven by a higher gross margin and slower operating expense growth.
Sales rose 11% to 9.895 billion euros on higher demand for its key drugs and vaccines and a favorable base of comparison.
Analysts expected business operating profit of 2.68 billion euros on sales of 9.64 billion euros, according to a poll of analysts by Visible Alpha.
Its business earnings per share were up 17% at 1.79 euros.
Sanofi stuck to its guidance for the year, expecting sales to grow by a mid-to-high single digit and business EPS at a low double-digit percentage, both at constant currencies.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 24, 2025 01:30 ET (05:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.